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Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is a periodic fever syn-
drome inherited in an autosomal dominant fashion. It stems from mutations in the TNFRSF1A
(accession number: NM_001065) gene expressing the receptor for tumor necrosis factor a. A
patient with TRAPS may present with prolonged episodes of fever attacks, abdominal pain, sev-
ere myalgia, and painful erythema on the trunk or extremities. Here, we report an 8-year-old
boy with febrile attacks occurring every 1–2 months and continuing for 3–4 days. The patient
experienced 40 C-fever attacks without chills. Approximately 80% of fever attacks were
accompanied by abdominal manifestations. Direct sequencing analysis was used to assess the
genomic DNA of the patient, and a heterozygous R426L mutation in exon 10 of the TNFRSF1A
gene in an autosomal dominant inheritance fashion was identified. Further genetic analyses
were also carried out on his parents. Due to the fact that the mutation was not inherited from
the parents, it was likely that R426L was a de novo and novel mutation in the TNFRSF1A gene,
which can trigger TRAPS or TRAPS-like symptoms.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).riz Genetic
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Tumor necrosis factor receptor-1 associated periodic syn-
drome (TRAPS) is a periodic fever syndrome and patients
may present with recurrent episodes of fever that normally
last for 1–3 weeks, in addition to severe localized inflam-
mation [1].
TRAPS arises from mutations of the tumor necrosis factor
receptor 1 gene (TNFRS1A) (accession number: NM_001065)
[2–5]. It was demonstrated that mutations of the TNFRSF1A
gene at 12P13.2 exert a pivotal role in susceptibility to the
disease [3,6,7]. TRAPS is inherited in an autosomal domi-
nant fashion, and genetic heterogeneity and variable pene-
trance are well documented in this regard. Mutational
analysis is required for confirmation of the diagnosis. Multi-
ple mutations have by far been detected in the TNFRSF1A
gene; of which 70 are associated with TRAPS [1,5,8].
Here, we report a case of TRAPS carrying an R426L muta-
tion in exon 10 of the TNFRSF1A gene. Presumably, it is the
first case of TRAPS reported in Iran and the first R426L
mutation in exon 10 giving rise to TRAPS.Fig. 1 New TNFRSF1A mutation (R426L) and pedigree of the
tumor necrosis factor receptor-associated periodic syndrome
family.Case report
The present case report was approved by the Ethics Com-
mittee of Tabriz University of Medical Sciences, Iran.
Informed consent was obtained from legal representative
of the patient for disclosure of the patients’ data. This case
was an 8-year-old boy who presented with a 2-year periodic
fever to the Outpatient Periodic Syndromes Clinic, Connec-
tive Tissue Diseases Research Center (CTRC), Imam Reza
Hospital, Tabriz University of Medical Sciences (Tabriz,
Iran). Roughly 80% of fever attacks were accompanied by
abdominal manifestations. Febrile attacks occurred every
1–2 months and the patient complained of fever for
7–10 days. During the attack, the patient had a 40 C fever
without chills. Except mild abdominal tenderness, no other
physical problems such as pharyngitis, skin lesions, and lym-
phadenopathy were observed during the attacks. Attacks
were not responsive to colchicine, although they responded
dramatically to steroids. No abnormality was diagnosed by
clinical examination or by routine laboratory tests between
the attacks; however, the patient showed leukocytosis and
high erythrocyte sedimentation rate during the attacks. It
is worth noting that this patient had a 1-year-old sister with
the same recurrent fever attacking every 1 or 2 months.
There was a negative familial history of periodic fever
syndromes for the patient.
Tests and measurements
The patient and his parents were referred to the CTRC for
further examination. DNA was extracted from the patient’s
leukocytes using a salting out technique, and mutation anal-
ysis was carried out by direct sequencing of two MEFV and
TNFRSF1A genes. Evaluation of the genetic results showed
no positive mutations for MEFV; however, a mutation was
detected in exon 10 of TNFRSF1A, resulting in a substitution
of leucine for arginine at residue 426 (R426L). The affected
phenotype led to amino acid alterations and wasPlease cite this article in press as: Khabazi A et al., A novel TNFRSF1A
ciated periodic syndrome, Hematol Oncol Stem Cell Ther (2016), http://dheterozygous as a variant with unknown clinical signifi-
cance. To confirm whether the mutation was responsible
for the symptoms, the same molecular analysis of the
TNFRSF1A gene was carried out on the parents. The final
results showed that the mutation was only present in the
patient but not in his parents (Fig. 1).
Discussion
TRAPS is the second most common periodic fever syndrome
inherited in an autosomal dominant fashion. Mutations of
the TNFRSF1A (12P13.2) gene have been demonstrated to
bring about the disease [1]. To date, six missense mutations
have been discovered in the target gene subsequent to the
identification of the candidate locus [4]. Elsewhere, four
novel mutations in TNFRSF1A have been detected [9]. This
led to screening of 18 families with patients afflicted with
TRAPS-like features [10]. The authors identified three previ-
ously reported and eight novel mutations in the gene and
concluded that the genetic basis in affected members was
heterogeneous.
More than 144 different TNFRSF1A gene mutations have
thus far been identified as causes of TRAPS (fevers data-
base: http://fmf.igh.cnrs.fr/infevers). Most of these muta-
tions are found in exons and introns 2, 3, 4, and 6, as well as
mutations in exons and introns 1, 5, 7, 8, and 10. Such muta-
tions normally diminish shedding of TNFR1 and eliminate an
endogenous antagonist to circulating tumor necrosis factor
(TNF), resulting in long-lasting activation of TNF signals,
although in some patients, other mechanisms are present
as follows: (1) an excess of retained surface TNFR1 leading
to a higher susceptibility to TNF [11]; (2) impaired TNF-
driven apoptosis because of less efficient binding of mutant
receptor to TNF [12] (3) giving rise to an unfolded protein
response or initiating TNF-independent signaling in the cell
by misfolded mutant TNFR1 [13].
The disease usually occurs in childhood. Typically,
the mean age of patients is 3 years [14]. The patients may
suffer from recurrent episodes of fever normally lastinggene mutation in a patient with tumor necrosis factor receptor-asso-
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Other symptoms including focal myalgia and sometimes
migratory myalgia, conjunctivitis, periorbital edema,
abdominal pain, monoarthritis, and rash are usually present
with fever attacks [1]. Approximately 15% of patients may
develop secondary AA (Amyloid A) amyloidosis, which pri-
marily affects the kidneys [14].
TRAPS is diagnosed by a history of episodic fever and one
or more accompanying symptoms. The long duration of
fever attacks, rash, eye, periorbital involvement, and focal
myalgia are hallmarks of TRAPS [14]. Family history is com-
monly positive in such patients, in spite of the fact that
some carriers of TRAPS mutations do not show any symp-
toms. The clinical diagnosis of TRAPS is confirmed by
genetic assessment of common mutations of the TNFR1
gene.
The reported case was an 8-year-old boy experiencing
recurrent fevers. Because of negative mutations in the MEFV
gene, long duration of attacks, inefficacy of colchicine in
the control of attacks, and good response to steroids, symp-
toms favored a possibility of TRAPS. Tests for TNFRSF1A
gene mutations showed a novel mutation in exon 10, leading
to the amino acid substitution and the affected phenotype
(R426L). The parents also underwent the tests to ensure
the pattern of inheritance and the results were negative
for the parents. As the unaffected parents did not carry
the R426L mutation while the patient did, the results indi-
cated a strong possibility of this unique mutation responsi-
ble for the symptoms. Three mutations in exon 10 have by
far been reported as a cause of TRAPS. These include
L330L, Y331X, and R341R from France, Turkey and The
Netherlands, respectively (in fevers database: http://fmf.
igh.cnrs.fr/infevers). It appears that R426L is a novel muta-
tion of the TNFRSF1A gene, which can cause TRAPS or
TRAPS-like symptoms.
In conclusion, patients with TRAPS or TRAPS-like symp-
toms mostly carry mutations in the TNFRSF1A gene; how-
ever, in the reported case, R426L was likely to be the
target mutation, as it was not inherited from the parents.
Nevertheless, further case documentation and research is
recommended.
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